TP53 and non-small cell lung carcinoma: Although the clinical trials of MLN8237 have been halted [69–72], our findings shed new light on this drug category for NSCLC treatment in that relative expression of AURKA and P53 may be of prognostic value and warrants further investigation with larger, prospective studies.